blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3549588

EP3549588 - PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER, COMPRISING TETRAARSENIC HEXOXIDE CRYSTALLINE POLYMORPH [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  31.03.2023
Database last updated on 19.10.2024
FormerRequest for examination was made
Status updated on  06.09.2019
FormerThe international publication has been made
Status updated on  16.06.2018
Most recent event   Tooltip13.12.2023Change - representative 
13.12.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Chemas Co., Ltd.
3rd Fl.
502 Bongeunsa-ro
Gangnam-gu
Seoul 06163 / KR
[2019/41]
Inventor(s)01 / BAE, Ill Ju
242-19, Nunkkotmaeul-gil
Imgye-myeon
Jeongseon-gun Gangwon-do 26112 / KR
02 / LIAN, Zenglin
Rm 412
No.5 B/D
Cuiweinanli
Cuiwei Road, Haidian District
Beijing 100036 / CN
 [2019/41]
Representative(s)Kraus & Lederer PartGmbB, et al
Thomas-Wimmer-Ring 15
80539 München / DE
[N/P]
Former [2019/41]Adam, Holger, et al
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
Application number, filing date17878050.804.12.2017
[2019/41]
WO2017KR14083
Priority number, dateKR2016016459505.12.2016         Original published format: KR 20160164595
[2019/41]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018105973
Date:14.06.2018
Language:KO
[2018/24]
Type: A1 Application with search report 
No.:EP3549588
Date:09.10.2019
Language:EN
[2019/41]
Search report(s)International search report - published on:KR14.06.2018
(Supplementary) European search report - dispatched on:EP25.05.2020
ClassificationIPC:A61K33/36, A61K31/285, A61P35/00
[2020/26]
CPC:
A61P35/00 (EP,CN); A61K33/36 (CN,KR,US); A61K31/285 (KR,US);
A61P1/16 (EP); C01G28/005 (EP,CN); C01G28/008 (US);
C01P2002/60 (US); C01P2002/72 (EP,CN,US); C01P2002/74 (EP);
C01P2002/77 (EP); C01P2002/88 (EP,US) (-)
Former IPC [2019/41]A61K33/36, A61K31/285
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/41]
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VORBEUGUNG ODER BEHANDLUNG VON LEBERKREBS MIT KRISTALLINEM TETRAARSENISCHEM HEXOXID-POLYMORPH[2019/41]
English:PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER, COMPRISING TETRAARSENIC HEXOXIDE CRYSTALLINE POLYMORPH[2019/41]
French:COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR OU TRAITER LE CANCER DU FOIE, COMPRENANT UN POLYMORPHE CRISTALLIN D'HEXAOXYDE DE TÉTRA-ARSENIC[2019/41]
Entry into regional phase27.05.2019Translation filed 
27.05.2019National basic fee paid 
27.05.2019Search fee paid 
27.05.2019Designation fee(s) paid 
27.05.2019Examination fee paid 
Examination procedure27.05.2019Examination requested  [2019/41]
11.12.2020Amendment by applicant (claims and/or description)
30.03.2023Despatch of a communication from the examining division (Time limit: M06)
06.10.2023Reply to a communication from the examining division
Fees paidRenewal fee
20.12.2019Renewal fee patent year 03
15.12.2020Renewal fee patent year 04
30.12.2021Renewal fee patent year 05
14.12.2022Renewal fee patent year 06
13.12.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]US2002028253  (BAE ILL-JU [KR], et al) [X] 1-4 * abstract * * paragraph [0019] * * paragraphs [0089] - [0094]; example 2; tables 1-4 * * paragraphs [0096] - [0099]; example 3 * * paragraph [0121]; example 9 * [I] 1-4;
 [XI]US2004018246  (BAE ILL-JU [KR], et al) [X] 1-4 * abstract * * paragraphs [0089] - [0094] * * paragraphs [0011] , [0019] , [0119] * [I] 1-4;
 [XI]US2004213737  (HUANG CHUN-YING [TW], et al) [X] 1-4 * abstract * * claim - * [I] 1-4;
 [A]WO2016123603  (VADDI KRISHNA [US], et al) [A] 1-4 * figure 3 *;
 [XI]  - Lin Jiang ET AL, "Original Article As 2 O 3 induces apoptosis in human hepatocellular carcinoma HepG2 cells through a ROS-mediated mitochondrial pathway and activation of caspases", Int J Clin Exp Med, (20150101), pages 2190 - 2196, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402797/pdf/ijcem0008-2190.pdf, XP055689326 [X] 1-4 * abstract * * page 2191; figure 1 * * page 2192; figure 2 * * page 2193; figure 3 * * page 2195, column l, paragraph 3 * [I] 1-4
 [T]  - Anonymous, "Arsenolite R050383 - RRUFF Database: Raman, X-ray, Infrared, and Chemistry", RRUFF database, (20200423), URL: https://rruff.info/Arsenolite/R050383, (20200423), XP055688966 [T] 1-4 * Powder Diffraction; page 2 *
 [T]  - CAMERON F. HOLDER ET AL, "Tutorial on Powder X-ray Diffraction for Characterizing Nanoscale Materials", ACS NANO, US, (20190723), vol. 13, no. 7, doi:10.1021/acsnano.9b05157, ISSN 1936-0851, pages 7359 - 7365, XP055689306 [T] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1021/acsnano.9b05157
 [T]  - ZDENKA Å LEJKOVEC ET AL, "Arsenic trioxide versus tetraarsenic oxide in biomedical research: misunderstandings and misinterpretations", BIOMETALS, KLUWER ACADEMIC PUBLISHERS, BO, (20110828), vol. 25, no. 1, doi:10.1007/S10534-011-9489-3, ISSN 1572-8773, pages 231 - 235, XP035005172 [T] 1-4 * abstract * * page 231, column r, line 1 - page 232, column l, paragraph 2 * * page 233, column r, paragraph 2 * * page 233, column r, paragraph l - page 234, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1007/s10534-011-9489-3
International search[XA]KR100272835B  (BAE IL JU [KR]) [X] 1, 3-4 * See abstract; claim 1; examples 1-2; experimental examples 1-5; figure 1. * [A] 2;
 [A]KR20020095835  (BAE IL JU [KR], et al) [A] 1-4 * See abstract; claims 1-5: figure 1. *;
 [A]US2008193560  (HWANG MICHAEL [US], et al) [A] 1-4* See abstract: claims 1-21. *;
 [A]KR20100054210  (CHONJISAN CO LTD [KR]) [A] 1-4 * See abstract; claims 1-9. *;
 [X]  - LEE, GWAN HUI, "Studies on the Anticancer Activity of Arsenichexoxide(As4O6", Targeted Basic Research Business. Korea Science and Engineering Foundation, (20030600), pages 1 - 4, XP009514975 [X] 1, 3-4 * , grant no. 1350004221 See abstract; paragraphs [1] and [2] of 3. Results and discussion; 4. Conclusion; figure 1. *
by applicantKR100272835B
    - BOSCH F.X. et al., "Primary liver cancer: worldwide incidence and trends", Gastroenterology, (20040000), vol. 127, no. s, pages s15 - s16
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.